Mirum Pharmaceuticals, Inc.
MIRM
$71.81
$0.290.41%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 64.09% | 61.20% | 42.93% | 89.37% | 107.68% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 64.09% | 61.20% | 42.93% | 89.37% | 107.68% |
| Cost of Revenue | 15.79% | 29.10% | -8.95% | 103.42% | 196.93% |
| Gross Profit | 81.04% | 72.34% | 72.08% | 85.54% | 87.87% |
| SG&A Expenses | 28.61% | 26.44% | 23.05% | 38.37% | 49.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.03% | 32.48% | 21.05% | 41.43% | 65.30% |
| Operating Income | 79.41% | 42.64% | 25.67% | 49.56% | 0.17% |
| Income Before Tax | 77.26% | 44.64% | 31.24% | 40.49% | 67.44% |
| Income Tax Expenses | -36.69% | 64.90% | -356.00% | 39.36% | 100.95% |
| Earnings from Continuing Operations | 76.21% | 41.94% | 33.28% | 39.65% | 66.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 76.21% | 41.94% | 33.28% | 39.65% | 66.72% |
| EBIT | 79.41% | 42.64% | 25.67% | 49.56% | 0.17% |
| EBITDA | 105.81% | 56.11% | 32.94% | 70.52% | 19.88% |
| EPS Basic | 77.40% | 44.27% | 42.60% | 48.09% | 73.15% |
| Normalized Basic EPS | 78.40% | 46.86% | -253.72% | 48.80% | 21.43% |
| EPS Diluted | 77.40% | 44.27% | 42.80% | 48.09% | 73.15% |
| Normalized Diluted EPS | 78.40% | 46.86% | -253.72% | 48.80% | 21.43% |
| Average Basic Shares Outstanding | 5.28% | 4.18% | 16.23% | 16.26% | 23.95% |
| Average Diluted Shares Outstanding | 5.28% | 4.18% | 16.23% | 16.26% | 23.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |